VA
RARE icon

Verdad Advisers’s Ultragenyx Pharmaceutical RARE Stock Holding History

Verdad Advisers’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$208K Buy
+6,223
New +$155K 0.2% 151

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Verdad Advisers's RARE Position: Q2 2026 in Review

Verdad Advisers opened a new position in Ultragenyx Pharmaceutical (RARE) in Q2 2026: 6,223 shares worth $208K. The stake represents 0.2% of the portfolio and ranks #151 among its holdings.

310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Verdad Advisers held 6,223 shares of Ultragenyx Pharmaceutical worth $208K as of Q2 2026.
  • Ultragenyx Pharmaceutical was a new Verdad Advisers position in Q2 2026.
  • Ultragenyx Pharmaceutical made up 0.2% of Verdad Advisers's portfolio in Q2 2026, its #151 holding.
  • 310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.